Home » Delcath’s Liver Cancer Treatment Device Suffers Regulatory Setback

Delcath’s Liver Cancer Treatment Device Suffers Regulatory Setback

February 23, 2011

Medical research firm Delcath Systems Inc. has suffered a setback in bringing its liver cancer treatment to market.
Post Star

19Jan
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements